Table 1.

Baseline characteristics of patient groups.1

AllGroup A (cTnI+/cTnAAb)Group B (cTnI+/cTnAAb+)Group B1 (first sample cTnAAb+)Group B2 (first sample cTnAAb)Group C (cTnI/cTnAAb)
n8153149514
Age, years64.3 (9.7)63.5 (9.9)65.1 (8.9)66.9 (8.9)61.9 (8.9)66.3 (10.2)
Women, n (%)22 (27.2)13 (24.5)6 (42.9)6 (66.7)0 (0)3 (21.4)
Body mass index, kg/m226.8 (4.0)27.2 (4.0)26.4 (3.5)26.8 (3.3)25.8 (4.2)25.8 (4.5)
Smoking, n (%)
 Never33 (40.7)19 (35.8)7 (50.0)4 (44.4)3 (60.0)7 (50.0)
 Former27 (33.3)17 (32.1)6 (42.9)5 (55.6)1 (20.0)4 (28.6)
 Current21 (25.9)17 (32.1)1 (7.1)0 (0)1 (20.0)3 (21.4)
Hypertension, n (%)31 (38.3)21 (39.6)7 (50.0)2 (22.2)5 (100.0)3 (21.4)
Diabetes, n (%)18 (22.2)12 (22.6)5 (35.7)3 (33.3)2 (40.0)1 (7.1)
Hypercholesterolemia, n (%)61 (75.3)39 (73.9)10 (71.4)6 (66.7)4 (80.0)12 (85.7)
Previous myocardial infarction, n (%)19 (23.5)11 (20.8)5 (35.7)4 (44.4)1 (20.0)3 (21.4)
Medication, n (%)
 Acetylsalicylic acid77 (95.1)50 (94.3)13 (92.9)8 (88.9)5 (100.0)14 (100)
 Beta-blocker68 (84.0)43 (81.1)12 (85.7)8 (88.9)4 (80.0)13 (92.9)
 ACE-inhibitor/AT-blocker15 (18.5)9 (17.0)6 (42.9)2 (22.2)3 (60.0)1 (7.1)
 Statin35 (43.2)22 (41.5)5 (35.7)3 (33.3)2 (40.0)8 (57.1)
Pro-BNP, ng/L780 (245–1652)855 (351–1717)861 (209–2522)609 (138–1650)861 (497–2930)270 (108–870)2
hs-CRP, mg/L5.7 (1.9–18.0)5.8 (2.1–22.0)10.9 (3.7–31.3)11.0 (4.6–14.0)10.0 (3.3–32.0)1.7 (0.7–7.1)23